1. Sirgo MA, Mills RJ, DeQuattro V. Effects of antihypertensive agents on circadian blood pressure and heart rate patterns. Review. Arch Intern Med. 1988; 148:2547–2552. PMID:
3058070.
Article
2. Degaute JP, van de Borne P, Linkowski P, Van Cauter E. Quantitative analysis of the 24-hour blood pressure and heart rate patterns in young men. Hypertension. 1991; 18:199–210. PMID:
1885228.
Article
3. O'Brien E, Sheridan J, O'Malley K. Dippers and non-dippers. Lancet. 1988; 2:397.
4. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002; 20:2183–2189. PMID:
12409956.
5. Metoki H, Ohkubo T, Kikuya M, Asayama K, Obara T, Hashimoto J, et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: the Ohasama study. Hypertension. 2006; 47:149–154. DOI:
10.1161/01.HYP.0000198541.12640.0f. PMID:
16380533.
6. Che X, Mou S, Zhang W, Zhang M, Gu L, Yan Y, et al. The impact of non-dipper circadian rhythm of blood pressure on left ventricular hypertrophy in patients with non-dialysis chronic kidney disease. Acta Cardiol. 2017; 72:149–155. DOI:
10.1080/00015385.2017.1291133. PMID:
28597784.
Article
7. Baumgart P. Circadian rhythm of blood pressure: internal and external time triggers. Chronobiol Int. 1991; 8:444–450. PMID:
1799926.
Article
8. Tanigawara Y, Yoshihara K, Kuramoto K, Arakawa K. Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis. Drug Metab Pharmacokinet. 2009; 24:376–388. PMID:
19745564.
Article
9. Chae D, Son M, Kim Y, Son H, Park K. Mechanistic model for blood pressure and heart rate changes produced by telmisartan in human beings. Basic Clin Pharmacol Toxicol. 2018; 122:139–148. DOI:
10.1111/bcpt.12856. PMID:
28805311.
Article
10. Staessen J, Celis H, De Cort P, Fagard R, Thijs L, Amery A. Methods for describing the diurnal blood pressure curve. J Hypertens Suppl. 1991; 9:S16–S18. PMID:
1795193.
11. Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG. Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther. 1998; 64:622–635. DOI:
10.1016/S0009-9236(98)90053-4. PMID:
9871427.
Article
12. van Rijn-Bikker PC, Snelder N, Ackaert O, van Hest RM, Ploeger BA, van Montfrans GA, et al. Nonlinear mixed effects modeling of the diurnal blood pressure profile in a multiracial population. Am J Hypertens. 2013; 26:1103–1113. DOI:
10.1093/ajh/hpt088. PMID:
23939415.
Article
13. Sällström B, Visser SA, Forsberg T, Peletier LA, Ericson AC, Gabrielsson J. A pharmacodynamic turnover model capturing asymmetric circadian baselines of body temperature, heart rate and blood pressure in rats: challenges in terms of tolerance and animal-handling effects. J Pharmacokinet Pharmacodyn. 2005; 32:835–859. DOI:
10.1007/s10928-005-0087-2. PMID:
16328099.
Article
14. Millar Craig MW, Mann S, Balasubramanian V, Raftery EB. Blood pressure circadian rhythm in essential hypertension. Clin Sci Mol Med Suppl. 1978; 4:391s–393s. PMID:
282095.